BMC launches three open access journals to support the translation of research into clinical practice
New OA journals expand publishing options for researchers and clinicians in immuno-oncology, fibrosis and neuroinflammation.
London | Heidelberg| New York, 11th August 2026
As researchers and clinicians work more closely to translate discoveries into patient benefit, BMC has launched three new full open access (OA) journals: Immuno-Oncology, Journal of Fibrosis, and Translational and Clinical Neuroinflammation. By providing trusted, dedicated homes for these fast-moving research communities, these launches respond to growing demand and will form part of Springer Nature's full OA portfolio, which now offers more than 770 journals across six brands.
Selene Carey, Publishing Director, BMC, said:
"Many of today's most significant advances in medicine depend on close collaboration between researchers and clinicians. These journals give each community a dedicated home to connect scientific discoveries with clinical practice, ensuring research reaches the people who can build on it."
All published research will be immediately and freely available worldwide, supporting greater visibility and impact for authors and readers. Across Springer Nature, authors publishing in our full OA journals benefit from increased visibility and impact, with the highest usage among mixed and pure OA publishers and an average of 7.6 citations per article, according to Springer Nature's latest Open Access Report.
The new journals include:
- Immuno-Oncology, focusing on the interface between immunology and cancer research, where laboratory findings can translate into improved understanding and treatment of cancer.
- Journal of Fibrosis, bringing together research across organ systems and disciplines to advance understanding, diagnosis and treatment of fibrotic diseases.
- Translational and Clinical Neuroinflammation, connecting research across the discovery-to-clinic continuum to advance understanding of neuroinflammatory diseases and support the development of new approaches to their treatment.
These journals join Sustainability, Uterine Research and Psychedelic Substances Research, launched earlier this year, building on BMC's more than 25 years of OA publishing across medicine and the life sciences.
BMC drives progress in the life sciences, health sciences, medicine and applied sciences, making robust research freely available to all. With over 300 open access journals and 25 years of experience leading the way in high-quality open science, BMC offers a trusted, supportive publishing experience and the visibility your work deserves. Visit biomedcentral.com and follow @BMC on social media.
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.
Daniela Kaltenborn | External Communications | daniela.kaltenborn@springernature.com
